lipid a - CISMeF

Preferred Label : lipid a;

MeSH definition : Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.;

CISMeF synonym : a, lipid;

Is substance : O;

Details

Origin ID

D008050;

UMLS CUI

C0023767;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- deficiency [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Lipid [UMLS semantic type]
- Lipid Measurement [NCIt concept]
- Lipids [HPMULTI term]
- Lipids [PASCAL theme]
- Lipids [PASCAL theme]
- Lipids [PASCAL descriptor]
- Lipids NOS low [MedDRA LLT]
- Lipids increased [MedDRA Preferred Term]
- dietary fats [MedlinePlus Topic]
- lipid [Blood Transfusion thesaurus concept]
- lipid [Artificial nutrition thesaurus concept]
- lipid containing [Radlex concept]
Currated CISMeF NLP mapping
- Lipid [FMA entity]
- Lipid [NCIt concept]
- Lipid (substance) [SNOMED CT concept]
- Lipids [MedDRA Preferred Term]
- Lipids NOS [MedDRA LLT]
- lipid [Radlex concept]
- lipid, nos [SNOMED Notion]
- lipids [IUPAC Term]
Indexing information
- 2-amino-6-O-(2-amino-2-deoxy-glucopyranosyl)-2-deoxyglucose [MeSH Supplementary Concept]
- B 1287 [MeSH Supplementary Concept]
- lipid X [MeSH Supplementary Concept]
- lipid Y [MeSH Supplementary Concept]
Record concept(s)
- lipid A [MeSH concept]
Related MeSH Supplementary Concept(s)
- 1-O-(5-(carboxy)pentanoyl)-2-deoxy-2-(2,2-difluorotetradecanamido)-3-O-(3-(tetradecanoyloxy)tetradecanoyl)-4-O-phosphonoglucopyranose [MeSH Supplementary Concept]
- 2,6-dideoxy-6-fluoro-2-(3-hydroxytetradecanamido)-3-O-((3-tetradecanoyloxy)tetradecanoyl)glucopyranose 4-(dihydrogen phosphate) [MeSH Supplementary Concept]
- 2-deoxy-2-((2,2-difluoro-3-hydroxytetradecanoyl)amino)-3-O-(3-(tetradecanoyloxy)tetradecanoyl)glucopyranose 4-phosphate [MeSH Supplementary Concept]
- 2-deoxy-2-((3R)-3-hydroxytetradecanamido)-3-O-((3-tetradecanoyloxy)tetradecanoyl)glucopyranosyl fluoride 4-(dihydrogen phosphate) [MeSH Supplementary Concept]
- 2-deoxy-2-(2-fluoro-3-hydroxytetradecanamido)-3-O-(3-hydroxytetradecanoyl)-4-O-phosphonoglucopyranose [MeSH Supplementary Concept]
- 3-deoxy-2-octulosonic acid(2)-lipid IV(A) [MeSH Supplementary Concept]
- 6'-O-(6-aminocaproyl)-4'-O-monophosphoryl lipid A [MeSH Supplementary Concept]
- 6-O-(2-deoxy-3-O-(3-hydroxytetradecanoyl)-2-((3-hydroxytetradecanoyl)amino)-glycopyranosyl)-2-deoxy-3-O-(3-hydroxytetradecanoyl)-2-((3-hydroxytetradecanoyl)amino)-glucopyranosylphosphonate [MeSH Supplementary Concept]
- A 103 [MeSH Supplementary Concept]
- A 113 [MeSH Supplementary Concept]
- A 503 [MeSH Supplementary Concept]
- A 601 [MeSH Supplementary Concept]
- A 602 [MeSH Supplementary Concept]
- A 603 [MeSH Supplementary Concept]
- AS01B adjuvant [MeSH Supplementary Concept]
- ASO2A adjuvant [MeSH Supplementary Concept]
- ASO4 mixture [MeSH Supplementary Concept]
- B 464 [MeSH Supplementary Concept]
- B 975 [MeSH Supplementary Concept]
- DT 5461 [MeSH Supplementary Concept]
- DY 9973 [MeSH Supplementary Concept]
- E 5531 [MeSH Supplementary Concept]
- E5564 [MeSH Supplementary Concept]
- GLA 27 [MeSH Supplementary Concept]
- GLA 40 [MeSH Supplementary Concept]
- GLA 60 [MeSH Supplementary Concept]
- GLA-AF adjuvant [MeSH Supplementary Concept]
- JTP 3309 [MeSH Supplementary Concept]
- N-(2,4,6-trinitrophenyl-6-aminocaproyl)-4'-monophosphoryl lipid A [MeSH Supplementary Concept]
- ONO 4007 [MeSH Supplementary Concept]
- RC524 [MeSH Supplementary Concept]
- RC529 [MeSH Supplementary Concept]
- SBAS4 adjuvant system [MeSH Supplementary Concept]
- SDZ 280-961 [MeSH Supplementary Concept]
- SDZ 281-288 [MeSH Supplementary Concept]
- SDZ 880-431 [MeSH Supplementary Concept]
- SDZ MRL 953 [MeSH Supplementary Concept]
- TLR4 agonist G100 [MeSH Supplementary Concept]
- adjuvant SBAS-2 [MeSH Supplementary Concept]
- adjuvant system 01 [MeSH Supplementary Concept]
- detox adjuvant [MeSH Supplementary Concept]
- diphosphoryl lipid A [MeSH Supplementary Concept]
- glucopyranosyl lipid-A [MeSH Supplementary Concept]
- hepatitis B vaccine AS04 [MeSH Supplementary Concept]
- hepta-1855 [MeSH Supplementary Concept]
- hexa-1685 [MeSH Supplementary Concept]
- lauroyl-lipid IVA [MeSH Supplementary Concept]
- lipid A precursors, bacterial [MeSH Supplementary Concept]
- lipid A-associated protein, bacteria [MeSH Supplementary Concept]
- monophosphoryl lipid A [MeSH Supplementary Concept]
- penta-1447 [MeSH Supplementary Concept]
- preparation 516 [MeSH Supplementary Concept]
- ragweed MATA MPL [MeSH Supplementary Concept]
- ribi adjuvant [MeSH Supplementary Concept]
- succinyl lipid A [MeSH Supplementary Concept]
Semantic type(s)
- Immunologic Factor [UMLS semantic type]
- Organic Chemical [UMLS semantic type]
Validated automatic mappings to NTBT
- Lipids [LOINC component]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients